What is the primary purpose of this 10-Q/A filing for Gilead Sciences?

This filing is an amendment to Gilead Sciences' Quarterly Report (10-Q) for the period ending September 29, 1996. Amendments are typically filed to correct errors, provide additional information, or update previously disclosed data in the original filing.

What kind of financial information can investors expect from a 10-Q filing from this era?

Investors can expect to find unaudited financial statements (balance sheet, income statement, cash flow statement), management's discussion and analysis of financial condition and results of operations, and details on any significant legal proceedings or risk factors. For a biotech company like Gilead in 1996, this would also likely include information on research and development activities and their associated costs.

Given the filing date, what was likely the key focus for Gilead Sciences in late 1996?

In late 1996, Gilead Sciences was likely focused on advancing its drug pipeline, particularly in areas like HIV/AIDS therapies, which was a significant area of research for the company. Investors would be interested in progress on clinical trials, potential regulatory submissions, and securing funding for ongoing research and development efforts.

What does the 'amendment' status of this filing imply for investors?

The amendment status suggests that the original 10-Q filing may have contained inaccuracies, omissions, or required further clarification. Investors should pay close attention to the amended sections to understand what has been changed or added, as these could be material to their investment decision.

GILD 10-Q Quarterly Report Q3 FY1996 — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. (GILD) filed an amendment to its 10-Q filing for the period ending September 29, 1996. This filing represents a snapshot of the company's financial position and operations during that late 1996 period. As a biotechnology company, investors would be keen to understand its progress in research and development, any key product updates, and its overall financial health, particularly its cash position and any emerging revenue streams. Given the historical context of this filing (February 1997), the focus would be on the company's early-stage development and any potential regulatory milestones it was approaching. Investors would also be looking for any significant changes in its financial statements, such as operating expenses, revenue growth (if any), and its ability to fund ongoing research and clinical trials, which are critical for a company at this stage of its lifecycle.

Key Highlights

1Filing is an amendment to the 10-Q for the period ending September 29, 1996.
2The filing date is February 24, 1997, indicating potential revisions or additions to previously submitted information.
3This filing provides a look into Gilead Sciences' financial and operational status in late 1996.
4As a biotechnology company in 1996, investors would focus on R&D progress and pipeline development.
5Key areas of interest for investors would include cash burn rate, funding for research, and any early signs of product commercialization or partnerships.
6The amendment nature suggests that further details or corrections to the original filing were deemed necessary by the company or the SEC.

GILEAD SCIENCES, INC. Quarterly Report (Amendment) for Q3 Ended Sep 30, 1996

Summary

Key Highlights

Frequently Asked Questions